Pemphigus Vulgaris
Conditions
Brief summary
This is a Phase III, randomized, double-blind, double-dummy, active-comparator, parallel-arm, multicenter study to evaluate the efficacy and safety of rituximab compared with MMF in participants with moderate-to-severely active PV requiring 60-120 milligrams per day (mg/day) oral prednisone or equivalent. Participants must have a confirmed diagnosis of PV within the previous 24 months (by skin or mucosal biopsy and immunohistochemistry) and evidence of active disease at screening. Approximately 135 participants will be enrolled at up to 60 centers worldwide. Participants will be randomized in a 1:1 ratio to receive either rituximab plus MMF placebo or rituximab placebo plus MMF. Randomization will be stratified by duration of illness. The study will consist of three periods: a screening period of up to 28 days, a 52-week double-blind treatment period, and a 48-week safety follow up period that begins at the time of study treatment completion or discontinuation.
Interventions
MMF matching placebo will be administered orally Q12H.
DRUGMycophenolate Mofetil
MMF will be administered at a starting dose of 500 milligrams (mg) Q12H and the dose will be titrated to achieve a goal of 1 gram (gm) Q12H.
DRUGRituximab
Rituximab will be administered at a dose of 1000 mg via IV infusion.
DRUGRituximab Placebo
Rituximab matching placebo will be administered via IV infusion.
Sponsors
Genentech, Inc.
Hoffmann-La Roche
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Confirmed diagnosis of PV within the previous 24 months, based on the presence of histological features of acantholysis via skin or mucosal biopsy and one of the following: tissue bound immunoglobulin G (IgG) antibodies by direct immunofluorescence on the surface of affected epithelium or serological detection of serum desmoglein-3 (DSg3) autoantibodies against epithelial cell surface either by indirect immunofluorescence microscopy or by enzyme-linked immunosorbent assay * Presence of moderate-to-severely active disease, defined as overall PDAI activity score of greater than or equal to (\>/=)15 * Receiving standard-of-care corticosteroids consisting of 60-120 mg/day oral prednisone or equivalent and, in the judgment of the investigator, expected to benefit from the addition of immunosuppressive therapy * For women who are not postmenopausal (\>/=12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use two effective methods of contraception, including at least one method with a failure rate of less than (\<) 1 percent (%) per year, during the treatment period and for at least 12 months after the last dose of study treatment Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception Barrier methods must always be supplemented with the use of a spermicide Examples of contraceptive methods with a failure rate of \< 1% per year (highly effective contraceptive methods) include tubal ligation, male sterilization, hormonal implants, established, proper use of combined oral or injected hormonal contraceptives, and certain intrauterine devices * For men (including those who have undergone a vasectomy): agreement to remain abstinent or use a condom during the treatment period and for at least 12 months after the last dose of study treatment and agreement to refrain from donating sperm during this same period Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the participant Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. In addition to male contraception, agreement to advise female partners of childbearing potential to use highly effective contraception during the study and for at least 12 months after the last dose of study treatment * Agreement to avoid excessive exposure to sunlight during study participation * Able to comply with the study protocol, in the investigator's judgment
Exclusion criteria
* Diagnosis of pemphigus foliaceus or evidence of paraneoplastic pemphigus or other non-PV autoimmune blistering disease * History of a severe allergic or anaphylactic reaction to humanized or murine monoclonal antibodies, or known hypersensitivity to any component of rituximab * Known hypersensitivity or contraindication to MMF, mycophenolic acid, polysorbate, or oral corticosteroids * Lack of peripheral venous access * Pregnant or lactating, or intending to become pregnant during the study Women who are not postmenopausal (\>/=12 months of non-therapy-induced amenorrhea) or surgically sterile must have two negative results with a sensitivity of \>/=25 milli-international units per milliliter (mIU/mL): one from a serum pregnancy test at Day -8 to Day -10 of screening and another from a urine pregnancy test at Day 1 prior to randomization * Participated in another interventional clinical trial within 28 days prior to randomization * Use of any investigational agent within 28 days or 5 elimination half-lives prior to randomization (whichever is the longer) * Significant cardiovascular or pulmonary disease (including obstructive pulmonary disease) * Evidence of any new or uncontrolled concomitant disease that, in the investigator's judgment, would preclude participant participation, including but not limited to nervous system, renal, hepatic, endocrine, malignant, or gastrointestinal disorders * Any concomitant condition that required treatment with oral or systemic corticosteroids within 12 weeks prior to randomization * Treatment with intravenous (IV) immunoglobulin (Ig), plasmapheresis, or other similar procedure within 8 weeks prior to randomization * Treatment with immunosuppressive medications (e.g., azathioprine, MMF) within 1 week prior to randomization * Treatment with cyclophosphamide within 12 weeks prior to randomization * History of or currently active primary or secondary immunodeficiency, including known history of HIV infection and other severe immunodeficiency blood disorders * Known active infection of any kind (excluding fungal infections of nail beds) or any major episode of infection requiring hospitalization or treatment with IV anti-infectives within 4 weeks prior to screening, or completion of oral anti-infectives within 2 weeks prior to randomization; entry into this study may be reconsidered once the infection has fully resolved * History of or current cancer, including solid tumors, hematologic malignancies, and carcinoma in situ (except complete excision of basal cell of the skin and squamous cell carcinoma of the skin that have been treated or excised and cured) * Currently active alcohol or drug abuse, or history of alcohol or drug abuse within 24 weeks prior to screening * Major surgery within 4 weeks prior to randomization, excluding diagnostic surgery * Treatment with rituximab or a B cell-targeted therapy (e.g., anti-cluster of differentiation \[CD\] 20 \[CD20\], anti CD22, or anti-B-lymphocyte stimulator \[BLyS\]) within 12 months prior to randomization * Treatment with a live or attenuated vaccine within 28 days prior to randomization; it is recommended that a participant's vaccination record and the need for immunization prior to study entry be carefully investigated * Evidence of abnormal liver enzymes or hematology laboratory values * Positive test results for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C virus (HCV) serology at screening
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of Participants (Excluding Telemedicine [TM] Participants) Who Achieved Sustained Complete Remission, Evaluated by the Pemphigus Disease Area Index (PDAI) Activity Score | From Baseline up to 52 Weeks (up to clinical cut-off date (CCOD) of 28 November 2018) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Total Number of Protocol Defined Disease Flares | From Baseline up to 52 Weeks (up to CCOD of 28 November 2018) | Disease flare is defined as appearance of three or more new lesions a month that do not heal spontaneously within 1 week, or by the extension of established lesions, in a participant who has achieved disease control. |
| Time to Initial Sustained Complete Remission | From Baseline up to 52 Weeks (up to CCOD of 28 November 2018) | — |
| Time to Protocol Defined Disease Flare | From Baseline up to 52 Weeks (up to CCOD of 28 November 2018) | Disease flare is defined as the appearance of three or more new lesions a month that do not heal spontaneously within 1 week or by the extension of established lesions in a participant who has achieved disease control. |
| Cumulative Oral Corticosteroid Dose | From Baseline up to 52 Weeks (up to CCOD of 28 November 2018) | — |
| Percentage of Participants With Adverse Events, Serious Adverse Events, and Corticosteroid-Related Adverse Events | Baseline up to 52 Weeks (up to CCOD of 28 November 2018) | An adverse event is any untoward medical occurrence in a participant to whom a medicinal product is administered and which does not necessarily have a causal relationship with this treatment. A serious adverse event is an adverse event that results in death or is life-threatening or requires/prolongs hospitalization or results in persistent/significant disability/incapacity or congenital abnormality/birth defect. Adverse events of Grade 3 of higher are severe and life-threatening adverse events CS-related adverse events - causality as determined by the investigator. |
| Percentage of Participants With Anti-Drug Antibodies (ADA) | Baseline up to 52 Weeks (up to CCOD of 28 November 2018) | Participants with treatment-induced and treatment-enhanced anti-drug antibodies. The clinical relevance of anti-rituximab antibody formation in RITUXAN treated pemphigus vulgaris (PV) participants is unclear. |
| Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Baseline; Weeks 16, 24, 40 and 52; (end of treatment: up to Week 52) (up to CCOD of 28 November 2018) | — |
| Change in Health-Related Quality of Life (HRQoL), as Measured by the Dermatology Life Quality Index (DLQI) Score | From Baseline up to 52 Weeks (up to CCOD of 28 November 2018) | Total DLQI scores range from 0 to 30 with higher DLQI scores reflecting greater impairment in a participant's health-related quality of life. The DLQI score is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. The measure type mean is the estimated mean from adjusted MMRM. |
Countries
Argentina, Australia, Brazil, Canada, France, Germany, Israel, Italy, Spain, Turkey (Türkiye), Ukraine, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Rituximab (RTX) Participants received rituximab by IV infusion on Days 1 and 15 with repeat administration on Days 168 and 182 provided specific safety criteria had been met. Participants also received MMF matching placebo orally twice daily (every 12 hours, Q12H) from Day 1 to Week 52. Participants who withdrew from the treatment period or who completed the total 52-week treatment period entered the safety follow up (SFU) period, and they were observed for 1 year and did not receive any further study treatment. | 67 |
| Mycophenolate Mofetil (MMF) Participants received Mycophenolate Mofetil (MMF) orally twice daily (every 12 hours, Q12H) from Day 1 to Week 52. Participants also received rituximab matching placebo by intravenous (IV) infusion on Days 1 and 15 with repeat administration on Days 168 and 182 provided specific safety criteria had been met. Participants who withdrew from the treatment period or who completed the total 52-week treatment period entered the safety follow up (SFU) period, and they were observed for 1 year and did not receive any further study treatment. | 68 |
| Total | 135 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Safety Follow-up (SFU) | Lost to Follow-up | 2 | 4 |
| Safety Follow-up (SFU) | Treated by not accepted treatment | 0 | 1 |
| Safety Follow-up (SFU) | Withdrawal by Subject | 5 | 0 |
| Treatment Period | Adverse Event | 1 | 3 |
| Treatment Period | Lost to Follow-up | 0 | 1 |
| Treatment Period | Non-compliance with study drug | 0 | 1 |
| Treatment Period | Withdrawal by Subject | 0 | 5 |
Baseline characteristics
| Characteristic | Rituximab (RTX) | Total | Mycophenolate Mofetil (MMF) |
|---|---|---|---|
| Age, Continuous | 50.66 Years STANDARD_DEVIATION 12.98 | 48.48 Years STANDARD_DEVIATION 13.16 | 46.34 Years STANDARD_DEVIATION 13.08 |
| Race/Ethnicity, Customized American Indian or Alaska Native | 0 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized Asian | 3 Participants | 4 Participants | 1 Participants |
| Race/Ethnicity, Customized Black or African American | 1 Participants | 3 Participants | 2 Participants |
| Race/Ethnicity, Customized Hispanic or Latino | 13 Participants | 34 Participants | 21 Participants |
| Race/Ethnicity, Customized Not Hispanic or Latino | 45 Participants | 86 Participants | 41 Participants |
| Race/Ethnicity, Customized Not Stated | 8 Participants | 13 Participants | 5 Participants |
| Race/Ethnicity, Customized Unknown | 14 Participants | 2 Participants | 13 Participants |
| Race/Ethnicity, Customized White | 49 Participants | 100 Participants | 51 Participants |
| Sex: Female, Male Female | 35 Participants | 73 Participants | 38 Participants |
| Sex: Female, Male Male | 32 Participants | 62 Participants | 30 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 67 | 1 / 68 | 0 / 66 | 0 / 58 |
| other Total, other adverse events | 42 / 67 | 41 / 68 | 2 / 66 | 3 / 58 |
| serious Total, serious adverse events | 15 / 67 | 10 / 68 | 4 / 66 | 1 / 58 |
Outcome results
Primary
Percentage of Participants (Excluding Telemedicine [TM] Participants) Who Achieved Sustained Complete Remission, Evaluated by the Pemphigus Disease Area Index (PDAI) Activity Score
Time frame: From Baseline up to 52 Weeks (up to clinical cut-off date (CCOD) of 28 November 2018)
Population: The modified intent-to-treat (mITT) population included participants in the ITT population (all randomized participants who received any part of an infusion of study drug or oral administration of study drug), excluding the 10 telemedicine (TM) participants. This population was used in the analyses of efficacy outcomes.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rituximab (RTX) | Percentage of Participants (Excluding Telemedicine [TM] Participants) Who Achieved Sustained Complete Remission, Evaluated by the Pemphigus Disease Area Index (PDAI) Activity Score | 40.3 Percentage of Participants |
| Mycophenolate Mofetil (MMF) | Percentage of Participants (Excluding Telemedicine [TM] Participants) Who Achieved Sustained Complete Remission, Evaluated by the Pemphigus Disease Area Index (PDAI) Activity Score | 9.5 Percentage of Participants |
p-value: <0.000195% CI: [14.7, 45.15]Cochran-Mantel-Haenszel
Secondary
Change in Health-Related Quality of Life (HRQoL), as Measured by the Dermatology Life Quality Index (DLQI) Score
Total DLQI scores range from 0 to 30 with higher DLQI scores reflecting greater impairment in a participant's health-related quality of life. The DLQI score is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. The measure type mean is the estimated mean from adjusted MMRM.
Time frame: From Baseline up to 52 Weeks (up to CCOD of 28 November 2018)
Population: The mITT population included participants in the ITT population (all randomized participants who received any part of an infusion of study drug or oral administration of study drug), excluding the 10 TM participants. This population was used in the analyses of efficacy outcomes. Only participants for whom data were collected are included in the analysis.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rituximab (RTX) | Change in Health-Related Quality of Life (HRQoL), as Measured by the Dermatology Life Quality Index (DLQI) Score | Baseline | 10.14 Scores on a Scale | Standard Error 7.89 |
| Rituximab (RTX) | Change in Health-Related Quality of Life (HRQoL), as Measured by the Dermatology Life Quality Index (DLQI) Score | Week 52 | -8.874 Scores on a Scale | Standard Error 0.532 |
| Mycophenolate Mofetil (MMF) | Change in Health-Related Quality of Life (HRQoL), as Measured by the Dermatology Life Quality Index (DLQI) Score | Baseline | 11.09 Scores on a Scale | Standard Error 8.52 |
| Mycophenolate Mofetil (MMF) | Change in Health-Related Quality of Life (HRQoL), as Measured by the Dermatology Life Quality Index (DLQI) Score | Week 52 | -6.002 Scores on a Scale | Standard Error 0.662 |
p-value: 0.001295% CI: [-4.577, -1.167]Mixed Model Repeated Measures
Secondary
Cumulative Oral Corticosteroid Dose
Time frame: From Baseline up to 52 Weeks (up to CCOD of 28 November 2018)
Population: The mITT population included participants in the ITT population (all randomized participants who received any part of an infusion of study drug or oral administration of study drug), excluding the 10 TM participants. This population was used in the analyses of efficacy outcomes.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Rituximab (RTX) | Cumulative Oral Corticosteroid Dose | 2775.00 milligram (mg) |
| Mycophenolate Mofetil (MMF) | Cumulative Oral Corticosteroid Dose | 4005.00 milligram (mg) |
p-value: 0.0005Wilcoxon (Mann-Whitney)
Secondary
Percentage of Participants With Adverse Events, Serious Adverse Events, and Corticosteroid-Related Adverse Events
An adverse event is any untoward medical occurrence in a participant to whom a medicinal product is administered and which does not necessarily have a causal relationship with this treatment. A serious adverse event is an adverse event that results in death or is life-threatening or requires/prolongs hospitalization or results in persistent/significant disability/incapacity or congenital abnormality/birth defect. Adverse events of Grade 3 of higher are severe and life-threatening adverse events CS-related adverse events - causality as determined by the investigator.
Time frame: Baseline up to 52 Weeks (up to CCOD of 28 November 2018)
Population: The safety population included all participants who were randomized and received any part of an infusion of study drug or oral administration of study drug.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Rituximab (RTX) | Percentage of Participants With Adverse Events, Serious Adverse Events, and Corticosteroid-Related Adverse Events | Participants with SAE | 22.4 Percentage of Participants |
| Rituximab (RTX) | Percentage of Participants With Adverse Events, Serious Adverse Events, and Corticosteroid-Related Adverse Events | Participants with AE | 85.1 Percentage of Participants |
| Rituximab (RTX) | Percentage of Participants With Adverse Events, Serious Adverse Events, and Corticosteroid-Related Adverse Events | Participants with Corticosteroid (CS)-Related AE | 34.3 Percentage of Participants |
| Rituximab (RTX) | Percentage of Participants With Adverse Events, Serious Adverse Events, and Corticosteroid-Related Adverse Events | Participants with CS-Related AE Grade 3 or higher | 1.5 Percentage of Participants |
| Mycophenolate Mofetil (MMF) | Percentage of Participants With Adverse Events, Serious Adverse Events, and Corticosteroid-Related Adverse Events | Participants with CS-Related AE Grade 3 or higher | 7.4 Percentage of Participants |
| Mycophenolate Mofetil (MMF) | Percentage of Participants With Adverse Events, Serious Adverse Events, and Corticosteroid-Related Adverse Events | Participants with Corticosteroid (CS)-Related AE | 38.2 Percentage of Participants |
| Mycophenolate Mofetil (MMF) | Percentage of Participants With Adverse Events, Serious Adverse Events, and Corticosteroid-Related Adverse Events | Participants with AE | 88.2 Percentage of Participants |
| Mycophenolate Mofetil (MMF) | Percentage of Participants With Adverse Events, Serious Adverse Events, and Corticosteroid-Related Adverse Events | Participants with SAE | 14.7 Percentage of Participants |
Secondary
Percentage of Participants With Anti-Drug Antibodies (ADA)
Participants with treatment-induced and treatment-enhanced anti-drug antibodies. The clinical relevance of anti-rituximab antibody formation in RITUXAN treated pemphigus vulgaris (PV) participants is unclear.
Time frame: Baseline up to 52 Weeks (up to CCOD of 28 November 2018)
Population: The safety population (all participants who were randomized and received any part of an infusion of study drug), only participants for whom data were collected are included in the analysis.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rituximab (RTX) | Percentage of Participants With Anti-Drug Antibodies (ADA) | 31.7 Percentage of Participants |
Secondary
Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN)
Time frame: Baseline; Weeks 16, 24, 40 and 52; (end of treatment: up to Week 52) (up to CCOD of 28 November 2018)
Population: The safety population included all participants who were randomized and received any part of an infusion of study drug or oral administration of study drug.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Rituximab (RTX) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Baseline (IgA) | 0 Percentage of Participants |
| Rituximab (RTX) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Week 40 (IgG) | 3.5 Percentage of Participants |
| Rituximab (RTX) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Week 52 (IgA) | 0 Percentage of Participants |
| Rituximab (RTX) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Week 52 (IgG) | 4.3 Percentage of Participants |
| Rituximab (RTX) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Week 24 (IgA) | 1.7 Percentage of Participants |
| Rituximab (RTX) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Baseline (IgM) | 7.6 Percentage of Participants |
| Rituximab (RTX) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Baseline (IgG) | 6.1 Percentage of Participants |
| Rituximab (RTX) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Week 16 (IgM) | 24.6 Percentage of Participants |
| Rituximab (RTX) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Week 16 (IgG) | 9.8 Percentage of Participants |
| Rituximab (RTX) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Week 24 (IgM) | 27.1 Percentage of Participants |
| Rituximab (RTX) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Week 40 (IgA) | 0 Percentage of Participants |
| Rituximab (RTX) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Week 40 (IgM) | 29.8 Percentage of Participants |
| Rituximab (RTX) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Week 24 (IgG) | 3.4 Percentage of Participants |
| Rituximab (RTX) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Week 52 (IgM) | 29.8 Percentage of Participants |
| Rituximab (RTX) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Week 16 (IgA) | 0 Percentage of Participants |
| Mycophenolate Mofetil (MMF) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Week 52 (IgM) | 28.6 Percentage of Participants |
| Mycophenolate Mofetil (MMF) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Baseline (IgA) | 0 Percentage of Participants |
| Mycophenolate Mofetil (MMF) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Week 16 (IgA) | 1.8 Percentage of Participants |
| Mycophenolate Mofetil (MMF) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Week 24 (IgA) | 2.2 Percentage of Participants |
| Mycophenolate Mofetil (MMF) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Week 40 (IgA) | 2.7 Percentage of Participants |
| Mycophenolate Mofetil (MMF) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Week 52 (IgA) | 3.6 Percentage of Participants |
| Mycophenolate Mofetil (MMF) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Baseline (IgG) | 6.0 Percentage of Participants |
| Mycophenolate Mofetil (MMF) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Week 16 (IgG) | 1.8 Percentage of Participants |
| Mycophenolate Mofetil (MMF) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Week 24 (IgG) | 2.2 Percentage of Participants |
| Mycophenolate Mofetil (MMF) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Week 40 (IgG) | 0 Percentage of Participants |
| Mycophenolate Mofetil (MMF) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Week 52 (IgG) | 0 Percentage of Participants |
| Mycophenolate Mofetil (MMF) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Baseline (IgM) | 11.9 Percentage of Participants |
| Mycophenolate Mofetil (MMF) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Week 16 (IgM) | 23.2 Percentage of Participants |
| Mycophenolate Mofetil (MMF) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Week 24 (IgM) | 28.3 Percentage of Participants |
| Mycophenolate Mofetil (MMF) | Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) | Week 40 (IgM) | 24.3 Percentage of Participants |
Secondary
Time to Initial Sustained Complete Remission
Time frame: From Baseline up to 52 Weeks (up to CCOD of 28 November 2018)
Population: The mITT population included participants in the ITT population (all randomized participants who received any part of an infusion of study drug or oral administration of study drug), excluding the 10 TM participants. This population was used in the analyses of efficacy outcomes.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Rituximab (RTX) | Time to Initial Sustained Complete Remission | NA Weeks |
| Mycophenolate Mofetil (MMF) | Time to Initial Sustained Complete Remission | NA Weeks |
p-value: 0.000395% CI: [1.97, 11.81]Log Rank
Secondary
Time to Protocol Defined Disease Flare
Disease flare is defined as the appearance of three or more new lesions a month that do not heal spontaneously within 1 week or by the extension of established lesions in a participant who has achieved disease control.
Time frame: From Baseline up to 52 Weeks (up to CCOD of 28 November 2018)
Population: The mITT population included participants in the ITT population (all randomized participants who received any part of an infusion of study drug or oral administration of study drug), excluding the 10 TM participants. This population was used in the analyses of efficacy outcomes.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Rituximab (RTX) | Time to Protocol Defined Disease Flare | NA Weeks |
| Mycophenolate Mofetil (MMF) | Time to Protocol Defined Disease Flare | NA Weeks |
p-value: <0.000195% CI: [0.06, 0.39]Log Rank
Secondary
Total Number of Protocol Defined Disease Flares
Disease flare is defined as appearance of three or more new lesions a month that do not heal spontaneously within 1 week, or by the extension of established lesions, in a participant who has achieved disease control.
Time frame: From Baseline up to 52 Weeks (up to CCOD of 28 November 2018)
Population: The mITT population included participants in the ITT population (all randomized participants who received any part of an infusion of study drug or oral administration of study drug), excluding the 10 TM participants. This population was used in the analyses of efficacy outcomes.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rituximab (RTX) | Total Number of Protocol Defined Disease Flares | 6 Number of Flares |
| Mycophenolate Mofetil (MMF) | Total Number of Protocol Defined Disease Flares | 44 Number of Flares |
p-value: <0.000195% CI: [0.05, 0.29]Negative Binominal Regression